Natural killer (NK) cells are an emerging cellular immunotherapy for patients with acute myeloid leukemia (AML); however, the best approach to maximize NK cell antileukemia potential is unclear. Cytokine-induced memory-like NK cells differentiate after a brief preactivation with interleukin-12 (IL-12), IL-15, and IL-18 and exhibit enhanced responses to cytokine or activating receptor restimulation for weeks to months after preactivation. We hypothesized that memory-like NK cells exhibit enhanced antileukemia functionality. We demonstrated that human memory-like NK cells have enhanced interferon-g production and cytotoxicity against leukemia cell lines or primary human AML blasts in vitro. Using mass cytometry, we found that memory-like NK cell functional responses were triggered against primary AML blasts, regardless of killer cell immunoglobulin-like receptor (KIR) to KIR-ligand interactions. In addition, multidimensional analyses identified distinct phenotypes of control and memory-like NK cells from the same individuals. Human memory-like NK cells xenografted into mice substantially reduced AML burden in vivo and improved overall survival. In the context of a first-in-human phase 1 clinical trial, adoptively transferred memory-like NK cells proliferated and expanded in AML patients and demonstrated robust responses against leukemia targets. Clinical responses were observed in five of nine evaluable patients, including four complete remissions. Thus, harnessing cytokine-induced memory-like NK cell responses represents a promising translational immunotherapy approach for patients with AML.
INTRODUCTION
Acute myeloid leukemia (AML) is a hematologic malignancy primarily of older individuals that remains a substantial clinical challenge (1) . Currently, less than 30% of AML patients are cured with standard therapies, and relapsed/refractory (rel/ref) AML patients who are not candidates for hematopoietic cell transplantation (HCT) have a poor prognosis and no curative treatment options (2, 3) . Cellular immunotherapy mediated by alloreactive T and NK cells administered in the context of an allogeneic HCT is an effective treatment for AML; however, most AML patients are not candidates for this procedure because it is associated with substantial treatment-related morbidity and mortality (4, 5) . An alternative approach that provides the immunotherapeutic benefits of allogeneic HCT without severe toxicity is the adoptive transfer of allogeneic lymphocytes that mediate the "graft versus leukemia" effect. This strategy may expand the option of cellular immunotherapy to most AML patients.
Natural killer (NK) cells are innate lymphoid cells that are important for host defense against pathogens and mediate antitumor immune responses (6, 7) . Major histocompatibility complex (MHC)-haploidentical NK cells exhibit antileukemia responses without causing "graft versus host disease" (GVHD) after HCT (8) , providing evidence of their utility as a cellular effector for leukemia patients. Allogeneic NK cell adoptive transfer is safe and can induce remissions in patients with leukemia (9) (10) (11) (12) ; however, these studies have been limited by inadequate persistence, expansion, and in vivo antileukemia activity of the adoptively transferred NK cells. Thus, one key barrier in the field is the need for biology-driven approaches to enhance NK cell antitumor functionality before adoptive transfer.
Although NK cells have traditionally been considered members of the innate immune system, paradigm-shifting studies in mice have identified memory-like properties after hapten exposure, virus infection, or combined interleukin-12 (IL-12), IL-15, and IL-18 cytokine preactivation (13, 14) . Cytokine-induced memory-like NK cells were defined by briefly preactivating murine NK cells with IL-12, IL-15, and IL-18, followed by adoptive transfer into syngeneic mice. Weeks to months later, memory-like NK cells had proliferated and exhibited enhanced restimulation responses to cytokines or triggering via activating receptors (15, 16) . This preactivation approach also resulted in antitumor responses to murine NK cell-sensitive cell lines after adoptive transfer in mice (17) . The potential translation of these findings as immunotherapy was established by the identification of human IL-12, IL-15, and IL-18-induced memory-like NK cells (18) . Key properties of human memory-like NK cells include enhanced proliferation, expression of the high-affinity IL-2 receptor abg (IL-2Rabg), and increased interferon-g (IFN-g) production after restimulation with cytokines or via activating receptors (19, 20) . However, the ability of human memory-like NK cells to respond to cancer target cells has not been extensively reported. We hypothesized that human cytokine-induced memory-like NK cells exhibit enhanced antileukemia properties. This was tested in vitro against primary AML blasts and in vivo in nonobese diabetic (NOD)/severe combined immunodeficient (SCID)/common gamma chain −/− (gc (Fig. 1A) . Memory-like NK cells exhibited enhanced IFN-g production in response to restimulation with both K562 leukemia cells (Fig. 1, A and B) and primary AML blasts (Fig. 1 , A and C). In addition, memory-like NK cells demonstrated significantly higher cytotoxicity compared to control NK cells from the same donors, which was dependent on NKG2D and DNAM-1 (P = 0.02; Fig. 1D and fig. S1 ). Consistent with augmented cytotoxicity, we observed increased expression of the cytotoxic effector protein granzyme B (Fig. 1 , E and F). To further define the differences between memory-like and control NK cells, we established a mass cytometry panel that included functionally relevant proteins to deeply immunophenotype NK cells.
Mass cytometry defines the differences between memory-like and control NK cells Mass cytometry allows for high-throughput analysis of a large number of parameters on single cells, and it has been used to deeply immunophenotype and track the diversity of human NK cells (21, 22) . We developed custom mass cytometry panels that include NK cell lineage, maturation, receptor repertoire, and functional capacity (tables S1 and S2), and using the viSNE clustering and visualization strategy (23), we identified the differences between control and memory-like NK cells (Fig. 2, A and B, and figs. S2 and S3). Control and memory-like NK cells were localized within separate areas of the viSNE map, indicative of distinct cellular islands ( Fig. 2A) . We confirmed significant differences in the expression of a number of markers that were previously reported (18, 19) , including CD94 (P = 0.002), NKG2A (P = 0.004), NKp46 (P = 0.04), and CD25 (P = 0.03) on the viSNE gated control and memory-like populations. Leveraging mass cytometry's expanded view of NK cell proteins, we observed increases in NKp30, NKp44, CD62L, CD27, and TRAIL and in the cytotoxic molecules perforin and granzyme B and also decreases in NKp80, compared to controls (Fig. 2B  and fig. S3 ). Thus, memory-like and control NK cells were identifiable as distinct populations when tracked with high NK cell marker dimensionality by mass cytometry. In addition, mass cytometry confirmed flow cytometry (24) (25) (26) , we next examined whether memory-like differentiation altered KIR diversity. We used mass cytometry to examine NK cells at baseline (naïve) and after control or memory-like differentiation in vitro at day 7 (table S1 and Fig. 1A ). The inverse Simpson diversity index of KIR expressed by naïve, control (day 7), and memory-like (day 7) NK cells was unaltered (Fig. 2C) (21, 27) , demonstrating that inhibitory KIR phenotypes present at baseline were stable in vitro. Consistent with this, the percent of KIR-positive NK cells was similar at day 7 between control and memory-like NK cell populations (Fig. 2D) .
In the setting of allogeneic HCT, donor KIR repertoire affects patient prognosis, highlighting the importance of the KIR to KIR-ligand mismatch for conventional NK cell anti-AML activity (24) (25) (26) 28) . To experimentally identify NK cell subsets that preferentially respond to primary AML blasts, we restimulated control and memory-like NK cells for 6 hours with primary AML blasts and assessed the expression of 36 parameters via mass cytometry (tables S2 to S4). Memory-like NK cells again produced more IFN-g when triggered with primary AML blasts compared to controls (Fig. 3, A and B) . We used spanning-tree progression analysis of density-normalized events (SPADE) to cluster the NK cells according to the expression of core NK cell markers and assessed each node (representing a distinct NK cell specificity) for IFN-g expression ( Fig. 3C) (29, 30) . The KIR-ligand interaction status of each node was defined to investigate their impact on memory-like and control NK cell responses. For a representative individual, we assigned the SPADE nodes as matched if they expressed KIR2DL2/KIR2DL3, which recognizes HLA-C1 present on the AML blasts. KIR2DL1 and KIR3DL1 did not have ligands present, and nodes that lacked KIR2DL2/KIR2DL3 were categorized as mismatched. Based on this approach, we observed the expected increased response in KIRmismatched versus KIR-matched node in IFN-g production in the control cells when triggered with AML blasts (Fig. 3 , D to F). However, memory-like NK cells produced increased IFN-g compared to control cells in both the KIR-ligand-matched and KIR-ligand-mismatched situations. Moreover, the IFN-g production by memory-like NK cells was similar in the KIR-matched and KIR-mismatched setting (Fig. 3 , D and E), which was reproducible across the seven individuals tested (Fig. 3E) . Furthermore, when we expanded our analysis to four different primary AML blasts, we observed a consistent increase in IFN-g production in KIR-matched memory-like NK cells compared to KIR-mismatched control-treated cells (Fig. 3F ). Because most memory-like NK cells express NKG2A, we assessed IFN-g production by NKG2A
− or NKG2A + KIR-ligand-matched or KIR-ligandmismatched NK cells and observed increased IFN-g production by memory-like NK cells compared to controls in both subpopulations (figs. S4, A to C). Cell surface CD107a, tumor necrosis factor, and macrophage inflammatory protein-1a were also increased on memorylike NK cells in these assays, compared to controls ( fig. S4D ). Thus, memory-like differentiation enhances IFN-g production in response to primary AML, regardless of whether memory-like NK cells expressed inhibitory KIR with a ligand present on the target AML blast.
Memory-like NK cells exhibit potent antileukemia functionality after transfer into NSG mice
To assess whether human memory-like NK cells maintain memory-like function in vivo, we used an adoptive transfer model with NSG mice (Fig. 4A ). After 7 days, memory-like NK cells were found to localize in key hematopoietic tissues, including bone marrow (BM), spleen, and blood (Fig. 4B ), and were found in similar numbers compared to control NK cells (Fig. 4C ). The expression of selected chemokine receptors was minimally changed after IL-12, IL-15, and IL-18 pre-activation, with the exception of reduced expression of CX3CR1 ( fig. S7 ). Memory-like NK cells also maintained their enhanced functionality as evidenced by increased IFN-g production in response to ex vivo restimulation with K562 leukemia cells after 7 days in NSG mice (Fig. 4, D 
and E).
To test the ability of human memory-like NK cells to control leukemia in vivo, we engrafted K562-luc (luciferase-expressing) leukemia cells in NSG mice and adoptively transferred human IL-12, IL-15, and IL-18-preactivated or control NK cells into groups of NSG mice on day 4 ( Fig. 4F ). Memory-like NK cells were significantly more effective in controlling K562 tumor cell growth in vivo using whole-body bioluminescence imaging (BLI) (P < 0.001; Fig. 4 , G and H). The enhanced leukemia control afforded by a single injection of human memory-like NK cells also resulted in improved survival of these mice (Fig. 4I) . . S5 ). Here, we report memorylike NK cell biology and antileukemia activity within the first nine evaluable patients treated at three different dose levels (Table 1) . Donor NK cells were purified by CD3 depletion followed by CD56-positive selection (10), preactivated for 12 to 16 hours with rhIL-12, rhIL-15, and rhIL-18 in a good manufacturing practice (GMP) laboratory, washed, and infused into AML patients who were preconditioned with fludarabine/cyclophosphamide (9) on day 0. After adoptive transfer, low-dose rhIL-2 was administered to support memory-like NK cells through their induced high-affinity IL-2Rabg (19) .
Three patients at dose level 1 (0.5 × 10 6 /kg), three patients at dose level 2 (1.0 × 10 6 /kg), and three patients at dose level 3 (all NK cells generated, capped at 10 × 10 6 /kg) were evaluable. Donor memory-like NK cells were tracked in the blood of all patients with informative HLA [using donor-or patient-specific anti-HLA monoclonal antibodies (mAbs)], peaked in frequency at 7 to 14 days after infusion and, as expected (9), decreased in number after recipient T cell recovery (Fig.  5 , A to C). Memory-like NK cells comprised >90% of blood NK cells at day 7 (Fig. 5, A and B) , with an average of 419 ± 166-fold increase (range, 39 to 1270) comparing day 1 and day 7 counts (Fig. 5C ). Donor memory-like NK cells had increased proliferation (Ki-67 + ) at days 3 and 7 (Fig. 5, D and E) . Similarly, assessments of the BM at day 8 after infusion revealed large percentages and absolute numbers of donor memory-like NK cells (Fig. 5, F to H), although there was heterogeneity between donor and recipient pairs, especially between NK cell dose levels ( fig. S6 ).
Donor memory-like NK cells exhibit enhanced functionality after adoptive transfer into patients with AML We next assessed donor and recipient blood NK cell IFN-g production from these patients after a short-term ex vivo restimulation triggered by K562 leukemia cells (Fig. 6, A to D) . These analyses revealed an increased frequency of IFN-g-positive donor, compared to recipient, NK cells (Fig.  6A ). More strikingly, these experiments revealed that the absolute number of donor IFN-g-producing NK cells was markedly increased, compared to the recipient NK cells in these samples (Fig. 6, B to D) . Similarly, the number of IFN-g-positive donor memory-like NK cells was greater than recipient NK cells in BM, although fewer patients had BM samples with adequate cell numbers for functional analyses (Fig. 6, E 
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Median IFN expression - patients were not evaluable because of inadequate donor cell collection caused by apheresis technical failure (n = 1) or death resulting from bacteremia with septic shock before day 14 (n = 1) or before day 35 (n = 2).
Of the nine evaluable patients (Table 1) , there were four CR/CRi and one MLFS by the IWG response criteria (31) , yielding an overall response rate of 55% and a CR/CRi rate of 45%. The changes in leukemia Published studies have identified comparable IL-12, IL-15, and IL-18-induced memory-like NK cell biology in mice and humans (15) (16) (17) (18) (19) . In mouse models, preactivation with IL-12, IL-15, and IL-18 has been shown to improve NK cell responses to lymphoma and melanoma cell lines in vivo, which required T cell-derived IL-2 (17). Although some phenotypic differences have been identified (18) , a clear approach to distinguishing memory-like from conventional NK cells from the same donor was lacking. Through mass cytometry and multidimensional data reduction algorithms, control and memory-like NK cells were identified in separate areas of viSNE maps, indicating a distinct phenotype and providing an approach to tracking memory-like NK cells in vivo. Currently, memory-like NK cells that emerge after IL-12, IL-15, and IL-18 preactivation are thought to result from a differentiation process that yields a long-term alteration of functional capacity; however, the molecular mechanisms that control this process are yet to be defined. This concept of differentiation is consistent with the distinct phenotype tracked by multidimensional analyses, and the observations that enhanced memory-like NK cell responses to restimulation are retained after extensive cell division and persisted for weeks to months after the initial preactivation (15, 18) . The phenotypic changes observed after IL-12, IL-15, and IL-18 preactivation include increased expression of inhibitory, activating, and cytokine receptors (CD94/NKG2A, NKp30, NKp44, NKp46, NKG2D, CD62L, and CD25), whereas other receptors appear unchanged (KIR, CD57, NKG2C, DNAM-1, CD137, and CD11b) or decreased (NKp80). Such dynamic changes in activating, inhibitory, cytokine, and adhesion receptors are also consistent with differentiation. Further, prolonged IL-12, IL-15, and IL-18 activation (for 5 days) resulted in reduced methylation of the IFN-g conserved activation, elucidation of molecular mechanisms controlling cytokineinduced memory would provide additional clarification of this issue.
Earlier work has set the stage for the use of allogeneic NK cells as adoptive immunotherapy for AML patients (9) (10) (11) (12) , harnessing the leukemia-targeting potential of NK cell allorecognition of MHCmismatched AML first identified after HCT (8) . Initial pioneering adoptive NK cell therapy clinical trials identified that an available lymphoid niche was essential for donor NK cell engraftment and expansion; however, clinical responses occurred in a minority of patients with limited duration (9) . This modest effect is consistent with the concept that combined modulatory approaches will be required to fully optimize NK cell adoptive immunotherapy for cancer patients, including (i) enhancement of NK cell targeting of cancer cells, (ii) augmentation of NK cell functional capacity, and (iii) elimination of inhibitory checkpoints or cellular negative regulators (33S). In the context of AML, NK cell allorecognition of MHC-haploidentical blasts has provided an established mode of targeting NK cells to myeloid leukemia via inhibitory receptor mismatch and activating receptor ligation. We discovered that IL-12, IL-15, and IL-18-induced memory-like NK cells exhibit enhanced triggering against AML regardless of KIR to KIR-ligand interactions, resulting in an expanded NK cell pool of AML-reactive effector cells. Because NKG2A is expressed on most memory-like NK cells, the interaction with HLA-E on AML blasts or bystander cells in the microenvironment remains a potentially important inhibitory pathway for memory-like NK cells. The functionality of memory-like NK cells is also enhanced in terms of cytotoxicity and IFN-g production. Thus, through brief combined cytokine stimulation, two aspects of the NK cell antitumor response have been improved. Most adoptive NK cell therapy studies to date use IL-2 or IL-15 to activate NK cells overnight before transfer. This strategy results in a short-term priming signal that increases NK cell functional capacity (33) , but the effect is rapidly lost after removal from the in vitro cytokine milieu and transfer into the patient. Here, we reasoned that the longerlasting increase in functional capacity afforded by memory-like NK cell differentiation, combined with improved AML recognition, would enhance in vivo expansion and antileukemia responses, resulting in a several week "window of opportunity" to attack AML blasts. Donor memory-like NK cells consistently expanded to become >90% of blood NK cells, as well as most BM NK cells. Because of concerns for cytokinerelease syndrome, our phase 1 study was intentionally initiated with a starting NK cell dose of (11) . Because our sample size was limited, this finding is hypothesis-generating and will need to be studied in more patients treated with IL-12, IL-15, and IL-18-preactivated NK cells. In our small sample set treated to date, these responses did not segregate with any KIRbased rules for NK cell allorecognition, although most patients studied had a KIR to KIR-ligand mismatch in the donor versus recipient direction. ) subcutaneously every other day for a total of six doses. Donor NK cell products were generated by purifying NK cells from a nonmobilized leukapheresis product using CD3 depletion followed by CD56-positive selection on a CliniMACS device (>90% CD56 + CD3 − ). Purified NK cells were preactivated with IL-12 (10 ng/ml), IL-15 (50 ng/ml), and IL-18 (50 ng/ml) for 12 to 16 hours under current GMP conditions. Samples were obtained from the peripheral blood (before treatment and at days 1, 3, 7, 8, 14, 21, 30, 60, and 100) and BM (before treatment and at days 8, 14, 30, 60, and 100) after the NK cell infusions. Clinical responses were defined by the revised IWG criteria for AML (31) . If cell numbers were limiting, analyses of NK cell number and phenotype were prioritized. All patients provided informed consent before participating and were treated at the Washington University Institutional Review Board (IRB)-approved clinical trial (Human Research Protection Office #201401085).
Reagents, mice, and cell lines Antihuman mAbs were used for flow and mass cytometry (tables S1, S2, and S6), including previously reported anti-HLA mAbs (34) . Endotoxinfree, recombinant human cytokines are described in the Supplemen- NK cell purification and cell culture Normal donor PBMCs were obtained from anonymous healthy platelet donors and isolated by Ficoll centrifugation (18, 19, 35) . NK cells were purified using RosetteSep (STEMCELL Technologies; routinely ≥95% CD56 + CD3 − ). KIR genotyping of donor PBMC was performed by Kashi Clinical Laboratories. Memory-like and control NK cells were generated as previously described (see the Supplementary Materials and Methods for more details) (18) .
Patient samples
Patients with newly diagnosed AML provided informed consent under the Washington University IRB-approved protocol (2010-11766) and were the source of primary AML blasts for in vitro resimulation experiments (table S4) . After informed consent, patient samples were also obtained from the first-in-human phase 1 clinical study of allogeneic donor memory-like NK cells in rel/ref AML (fig. S5 ). Patient peripheral blood or BM aspirate was obtained at the indicated time point after NK cell infusion, and PBMCs were isolated by Ficoll centrifugation and immediately used in experiments.
Functional assays to assess cytokine production Control and memory-like NK cells were harvested after a rest period of 7 days to mimic transfer into a patient and to allow memory-like NK cell differentiation to occur. Cells were then restimulated in a standard functional assay (18, 19, 35) . Cells were stimulated with K562 leukemia targets or freshly thawed primary AML blasts (effector/target ratio of 5:1, unless otherwise indicated). Further details are provided in the Supplementary Materials and Methods.
Flow-based killing assay Flow-based killing assays were performed by co-incubating memorylike or control NK cells with carboxyfluorescein diacetate succinimidyl ester-labeled K562 cells for 4 hours and assaying 7-aminoactinomycin D uptake as described (18, 19, 35) .
Adoptive transfer of human memory-like NK cells into NSG mice Purified control (5 × 10 6 ; ≥95% CD56 + CD3 − ) or IL-12, IL-15, and IL-18-preactivated NK cells were injected retro-orbitally into NSG mice. Mice received rhIL-2 (50,000 IU) through intraperitoneal injection every other day to support the adoptively transferred NK cells. After 7 days, the mice were sacrificed, and organs (spleen, blood, and BM) were assessed for the presence of transferred cells. NSG splenocytes were also examined for intracellular IFN-g production after restimulation with K562 leukemia targets.
In vivo BLI
For BLI experiments, mice were treated as described in the Supplementary Materials and Methods. For imaging, mice were injected intraperitoneally with D-luciferin (150 mg/g) (Biosynth) in PBS and imaged using the IVIS 100 (Caliper). BLI was performed at the indicated time points.
Flow cytometric analysis
Cell staining was performed as described (18, 19, 35) , and data were acquired on a Gallios flow cytometer (Beckman Coulter) and analyzed using Kaluza (Beckman Coulter) or FlowJo (Tree Star) software.
Mass cytometry
All mass cytometry data were collected on a CyTOF2 mass cytometer (Fluidigm) and analyzed using Cytobank (36) . Mass cytometry data were analyzed using previously described methods (37) . For detailed information, refer to the Supplementary Materials and Methods. Diversity was assessed on eight individual donors at baseline (freshly thawed PBMCs or thawed pure NK cells), after control treatment or memorylike differentiation (described above) using the Boolean gating strategy described in fig. S2 (21, 22) . Event counts were used to generate inverse Simpson index for KIR2DL1, KIR2DL1/KIR2DL2, KIR3DL1, KIR2DS4, and KIR2DL5 expression.
Statistical analysis
Before statistical analyses, all data were tested for normal distribution (D'Agostino-Pearson omnibus normality test). If data were not normally distributed, the appropriate nonparametric tests were used (GraphPad Prism v5.0), with all statistical comparisons indicated in the figure legends. Uncertainty is represented in the figures as SEM, except as indicated in the figure legends. All comparisons used a two-sided a of 0.05 for significance testing. Table S1 . NK cell phenotypic mass cytometry panel design, reagents, and clustering usage. Table S2 . NK cell functional mass cytometry panel design, reagents, and clustering usage. Table S3 . Characteristics of normal donors used in mass cytometry functional experiments. Table S4 . Characteristics of AML samples used for in vitro NK cell functional assays. Table S5 . Patient HLA and donor KIR characteristics for evaluable donor-patient pairs treated in the phase 1 clinical trial. Table S6 . Flow cytometry mAbs. Reference (38) 
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